JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was given a market outperform rating by JMP Securities analyst Adam Cutler. JMP continues to track weekly Factive and Auxilium's Testim prescription volumes using NDC Health data. For the week ended Jan. 20, NDC reported that Factive total prescriptions were 6,108, representing 0.89% of weekly prescriptions for the quinolone class of antibiotics, compared with 6,944 total prescriptions in the previous week, representing 0.93% of weekly prescriptions from the quinolone class. Shares of the Waltham, Mass., pharmaceutical company were down 3 cents, or 1.43%, at $2.07 on volume of 261,520 shares versus the three-month running average of 565,570 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.